CAR-T therapy for blood cancers: how do patients fare years later?
Knowledge-focused
Not yet recruiting
This study follows up with 49 people who have relapsed acute myeloid leukemia or myelodysplastic syndrome and previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will monitor long-term side effects and overall survival to understand the lasting safety a…
Sponsor: ARCE Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 04, 2026 02:37 UTC